Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the FDA approval of bremelanotide for premenopausal women with hypoactive sexual desire disorder and reports no clinical results.

VYC-12L effectively improves skin smoothness, reduces fine lines, and boosts hydration.

This study reports that hair loss may be a rare side effect of levetiracetam in epilepsy patients and appears reversible upon dose reduction or cessation.

This study evaluated a levan-based polysaccharide, POLEVAN®, in shampoo formulations and reported that it significantly increased hair glossiness by 24%, allowed a reduction of surfactant content by up to 50% without affecting foam, and maintained scalp moisturization similar to hyaluronic acid in a clinical setting.

This study found that a low-dose oral contraceptive containing dienogest provides effective contraception, improves cycle stability, and may reduce excessive scalp and skin oiliness, with high user satisfaction.

This study found that VYC-15L (Juvéderm Volbella XC) was safe and effective for enhancing lip and perioral areas, achieving higher lip fullness improvement and fewer severe injection site reactions compared to NASHA, with effects lasting up to one year.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Lemon-derived vesicles may help hair grow.

This case report describes a 13-year-old girl with epilepsy who experienced hair loss within two months of starting levetiracetam, marking it as the first report of this side effect in this age group.

This study found that VEGF expression and microvessel density in hair follicles of Liaoning cashmere goats follow a bimodal pattern correlated with hair development throughout the year.

In this study, both VEPA and ML-Y1 treatment regimens for older patients with non-Hodgkin's lymphoma showed similar response and survival rates, but neither was sufficient, indicating the need for a more effective approach.

In this clinical study, Verilich hair serum significantly reduced hair shedding by 40% or more in 75% of female patients with Telogen Effluvium and Female Pattern Hair Loss after one month of use.

This research reported that eflornithine HCl 13.9% cream generally has a favorable dermal safety profile for managing unwanted facial hair in women, though it can cause mild irritation under certain conditions.

This study suggests that extracellular vesicles derived from Saccharomyces cerevisiae may enhance hair follicle-related cellular processes, highlighting their potential for biomedical and cosmetic applications.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This study found that both levetiracetam and valproate sodium effectively reduced seizure frequency and duration in patients with refractory epilepsy, but levetiracetam had fewer side effects related to liver enzyme changes.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study reported that extended-release valproate significantly reduced seizure frequency and improved quality of life in epilepsy patients over six months, despite some adverse effects like weight gain and tremor.

This study found that a serum combining recombinant growth factors and plant-derived EVs significantly increased eyelash length and density without causing skin hyperpigmentation in healthy female participants over eight weeks.

This study found that eflornithine HCl 13.9% cream reduces unwanted facial hair growth in women, with effects seen in up to 60% of participants over 4-8 weeks, with mostly minor skin irritation reported.

In this study, extracellular vesicles from Saccharomyces cerevisiae demonstrated multifunctional bioactivity, enhancing cell proliferation and migration, reducing inflammation, and promoting collagen gene expression in hair follicle–related cells.

In this study, behavioral disturbances were commonly observed with levetiracetam, while somnolence was frequently reported with oxcarbazepine among patients with refractory epilepsy.

The vellus index is a simple, quick, and reliable method to assess and monitor hair growth, especially in hirsutism.

This case report describes a 19-year-old woman with systemic lupus erythematosus and telogen effluvium, who experienced new hair growth and increased hair density after 90 days of treatment with 2% topical minoxidil and oral keratin-based antioxidants.

This compilation details various potential side effects and interactions of vitamin A, but it reports no new research findings.

This study found that serum VEGF levels were lower in women with telogen effluvium compared to healthy controls, indicating a possible role of VEGF in the condition's pathogenesis.

This prospective observational study evaluated the use of Verilich serum for hair loss and found that 71.4% of chronic telogen effluvium patients saw significant improvement in hair shedding within 2 months, with no adverse events reported.

This study found that while Er:YAG laser therapy can initially improve the appearance of eruptive vellus hair cysts, it was ineffective in preventing early recurrences due to limitations in ablation depth.